Every 10-Q that RenovoRx, Inc. (RNXT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RNXT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNXT filings page.
RenovoRx, Inc. reported strong early commercialization momentum for its RenovoCath device while remaining deeply loss-making. Q2 2026 revenue was $909,000, up from $422,000 a year earlier, with six‑month revenue of $1.47 million versus $619,000 in 2025, reflecting broader adoption across active cancer centers.
Despite higher revenue, the company recorded a Q2 2026 net loss of $2.91 million and a six‑month net loss of $6.43 million, driven mainly by $8.06 million in operating expenses as it builds out commercial and clinical capabilities. Operating cash outflows were $6.58 million for the first half, partially offset by a March 2026 private placement that raised $10.0 million gross, leaving cash and cash equivalents of $9.48 million at June 30, 2026.
Management states current liquidity is expected to fund operations for at least 12 months from the report date, into the second half of 2027, but acknowledges that longer‑term growth, continued RenovoCath commercialization, and the Phase III TIGeR‑PaC trial for its IAG drug‑device candidate will likely require additional capital. The company also highlights multiple Orphan Drug Designations and continued progress toward completing TIGeR‑PaC, with clinical and investigator‑initiated studies intended to broaden its TAMP targeted‑delivery platform.
RenovoRx, Inc. reported first-quarter 2026 results showing rapid early commercialization but continued losses. Revenue from RenovoCath device sales reached $563,000, up from $197,000 a year earlier and described as a 136% quarter-over-quarter increase versus the fourth quarter of 2025. Gross profit was $479,000, but operating expenses of $3.9 million led to a net loss of $3.5 million, or $0.09 per share.
Cash and cash equivalents were $12.4 million as of March 31, 2026, supported by a March 2026 private placement that raised approximately $10.0 million gross. Management believes this cash will fund operations for at least 12 months.
The company is expanding its commercial footprint for RenovoCath, growing from 8 active cancer centers at the end of 2025 to 16 as of May 6, 2026, with 32 more centers in its pipeline. RenovoRx is also nearing full enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, with 106 of 114 patients randomized and 74 of 86 required events observed, and continues to anticipate final data in mid to late 2027.
RenovoRx (RNXT) filed its Q3 2025 report, showing early commercial traction and continued losses as it builds out its device-led strategy. Revenue reached $266,000 for the quarter and $885,000 year‑to‑date from RenovoCath sales, producing quarterly gross profit of $213,000.
Operating expenses were $3.4 million, leading to a net loss of $2.9 million for Q3 and $8.2 million for the first nine months. Cash and cash equivalents were $10.0 million as of September 30, 2025, helped by a February underwritten offering that raised $10.8 million in net proceeds. The company reported a common stock warrant liability of $1.11 million and recorded $272,000 of inventory as it scales manufacturing under a supply agreement with $0.7 million in non‑cancellable commitments.
The company concluded current cash will not fund operations for the next 12 months from issuance, indicating a need for additional financing. Shares outstanding were 36,649,916 as of November 12, 2025.